Download PDF
Semin Thromb Hemost 2021; 47(03): 254-260
DOI: 10.1055/s-0041-1725065
Review Article

Effect of Heparanase and Heparan Sulfate Chains in Hemostasis

Yona Nadir
1   Thrombosis and Hemostasis Unit, Rambam Health Care Campus, The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Heparanase, the only mammalian enzyme known to degrade heparan sulfate chains, affects the hemostatic system through several mechanisms. Along with the degrading effect, heparanase engenders release of syndecan-1 from the cell surface and directly enhances the activity of the blood coagulation initiator, tissue factor, in the coagulation system. Upregulation of tissue factor and release of tissue factor pathway inhibitor from the cell surface contribute to the prothrombotic effect. Tissue factor pathway inhibitor and the strongest physiological anticoagulant antithrombin are attached to the endothelial cell surface by heparan sulfate. Hence, degradation of heparan sulfate induces further release of these two natural anticoagulants from endothelial cells. Elevated heparanase procoagulant activity and heparan sulfate chain levels in plasma, demonstrated in cancer, pregnancy, oral contraceptive use, and aging, could suggest a potential mechanism for increased risk of thrombosis in these clinical settings. In contrast to the blood circulation, accumulation of heparan sulfate chains in transudate and exudate pleural effusions induces a local anticoagulant milieu. The anticoagulant effect of heparan sulfate chains in other closed spaces such as peritoneal or subdural cavities should be further investigated.

Keywords

heparanase - heparan sulfate - tissue factor - tissue factor pathway inhibitor - antithrombin


Publication History

Article published online:
01 April 2021

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Vlodavsky I, Elkin M, Abboud-Jarrous G. et al. Heparanase: one molecule with multiple functions in cancer progression. Connect Tissue Res 2008; 49 (03) 207-210
    CrossrefPubMedGoogle Scholar
  • 2 Sanderson RD, Elkin M, Rapraeger AC, Ilan N, Vlodavsky I. Heparanase regulation of cancer, autophagy and inflammation: new mechanisms and targets for therapy. FEBS J 2017; 284 (01) 42-55
    CrossrefPubMedGoogle Scholar
  • 3 Nadir Y, Vlodavsky I, Brenner B. Heparanase, tissue factor, and cancer. Semin Thromb Hemost 2008; 34 (02) 187-194
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Vlodavsky I, Eldor A, Haimovitz-Friedman A. et al. Expression of heparanase by platelets and circulating cells of the immune system: possible involvement in diapedesis and extravasation. Invasion Metastasis 1992; 12 (02) 112-127
    PubMedGoogle Scholar
  • 5 Parish CR, Freeman C, Hulett MD. Heparanase: a key enzyme involved in cell invasion. Biochim Biophys Acta 2001; 1471 (03) M99-M108
    PubMedGoogle Scholar
  • 6 Freeman C, Parish CR. Human platelet heparanase: purification, characterization and catalytic activity. Biochem J 1998; 330 (Pt 3): 1341-1350
    CrossrefPubMedGoogle Scholar
  • 7 Goshen R, Hochberg AA, Korner G. et al. Purification and characterization of placental heparanase and its expression by cultured cytotrophoblasts. Mol Hum Reprod 1996; 2 (09) 679-684
    CrossrefPubMedGoogle Scholar
  • 8 Tatour M, Shapira M, Axelman E. et al. Thrombin is a selective inducer of heparanase release from platelets and granulocytes via protease-activated receptor-1. Thromb Haemost 2017; 117 (07) 1391-1401
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Teien AN, Abildgaard U, Höök M. The anticoagulant effect of heparan sulfate and dermatan sulfate. Thromb Res 1976; 8 (06) 859-867
    CrossrefPubMedGoogle Scholar
  • 10 Chappell D, Jacob M, Hofmann-Kiefer K. et al. Antithrombin reduces shedding of the endothelial glycocalyx following ischaemia/reperfusion. Cardiovasc Res 2009; 83 (02) 388-396
    CrossrefPubMedGoogle Scholar
  • 11 Lwaleed BA, Bass PS. Tissue factor pathway inhibitor: structure, biology and involvement in disease. J Pathol 2006; 208 (03) 327-339
    CrossrefPubMedGoogle Scholar
  • 12 Valentin S, Larnkjer A, Ostergaard P, Nielsen JI, Nordfang O. Characterization of the binding between tissue factor pathway inhibitor and glycosaminoglycans. Thromb Res 1994; 75 (02) 173-183
    CrossrefPubMedGoogle Scholar
  • 13 Nadir Y, Brenner B, Gingis-Velitski S. et al. Heparanase induces tissue factor pathway inhibitor expression and extracellular accumulation in endothelial and tumor cells. Thromb Haemost 2008; 99 (01) 133-141
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Nadir Y, Brenner B, Zetser A. et al. Heparanase induces tissue factor expression in vascular endothelial and cancer cells. J Thromb Haemost 2006; 4 (11) 2443-2451
    CrossrefPubMedGoogle Scholar
  • 15 Nadir Y, Brenner B, Fux L, Shafat I, Attias J, Vlodavsky I. Heparanase enhances the generation of activated factor X in the presence of tissue factor and activated factor VII. Haematologica 2010; 95 (11) 1927-1934
    CrossrefPubMedGoogle Scholar
  • 16 Baker AB, Gibson WJ, Kolachalama VB. et al. Heparanase regulates thrombosis in vascular injury and stent-induced flow disturbance. J Am Coll Cardiol 2012; 59 (17) 1551-1560
    CrossrefPubMedGoogle Scholar
  • 17 Nadir Y, Henig I, Naroditzky I, Paz B, Vlodavsky I, Brenner B. Involvement of Heparanase in early pregnancy losses. Thromb Res 2010; 125 (05) e251-e257
    CrossrefPubMedGoogle Scholar
  • 18 Nadir Y, Kenig Y, Drugan A, Zcharia E, Brenner B. Involvement of heparanase in vaginal and cesarean section deliveries. Thromb Res 2010; 126 (06) e444-e450
    CrossrefPubMedGoogle Scholar
  • 19 Nadir Y, Kenig Y, Drugan A, Shafat I, Brenner B. An assay to evaluate heparanase procoagulant activity. Thromb Res 2011; 128 (04) e3-e8
    CrossrefPubMedGoogle Scholar
  • 20 Matan M, Axelman E, Brenner B, Nadir Y. Heparanase procoagulant activity is elevated in women using oral contraceptives. Hum Reprod 2013; 28 (09) 2372-2380
    CrossrefPubMedGoogle Scholar
  • 21 Nadir Y, Sarig G, Axelman E. et al. Heparanase procoagulant activity is elevated and predicts survival in non-small cell lung cancer patients. Thromb Res 2014; 134 (03) 639-642
    CrossrefPubMedGoogle Scholar
  • 22 Peled E, Rovitsky A, Axelman E, Norman D, Brenner B, Nadir Y. Increased heparanase level and procoagulant activity in orthopedic surgery patients receiving prophylactic dose of enoxaparin. Thromb Res 2012; 130 (01) 129-134
    CrossrefPubMedGoogle Scholar
  • 23 Peled E, Melamed E, Portal TB. et al. Heparanase procoagulant activity as a predictor of wound necrosis following diabetic foot amputation. Thromb Res 2016; 139: 148-153
    CrossrefPubMedGoogle Scholar
  • 24 Nadir Y, Saharov G, Hoffman R. et al. Heparanase procoagulant activity, factor Xa, and plasminogen activator inhibitor 1 are increased in shift work female nurses. Ann Hematol 2015; 94 (07) 1213-1219
    CrossrefPubMedGoogle Scholar
  • 25 Hu Y, Atik A, Yu H. et al. Serum heparanase concentration and heparanase activity in patients with retinal vein occlusion. Acta Ophthalmol 2017; 95 (01) e62-e66
    CrossrefPubMedGoogle Scholar
  • 26 Bayam E, Kalçık M, Gürbüz AS. et al. The relationship between heparanase levels, thrombus burden and thromboembolism in patients receiving unfractionated heparin treatment for prosthetic valve thrombosis. Thromb Res 2018; 171: 103-110
    CrossrefPubMedGoogle Scholar
  • 27 Levi M. Pathogenesis and diagnosis of disseminated intravascular coagulation. Int J Lab Hematol 2018; 40 (Suppl. 01) 15-20
    CrossrefPubMedGoogle Scholar
  • 28 Matan M, King D, Peled E. et al. Heparanase level and procoagulant activity are reduced in severe sepsis. Eur J Haematol 2018; 100 (02) 182-188
    CrossrefPubMedGoogle Scholar
  • 29 Martin L, De Santis R, Koczera P. et al. The synthetic antimicrobial peptide 19-2.5 interacts with heparanase and heparan sulfate in murine and human sepsis. PLoS One 2015; 10 (11) e0143583
    CrossrefPubMedGoogle Scholar
  • 30 Hofmann-Kiefer KF, Kemming GI, Chappell D. et al. Serum heparan sulfate levels are elevated in endotoxemia. Eur J Med Res 2009; 14: 526-531
    CrossrefPubMedGoogle Scholar
  • 31 Xu X, Quiros RM, Maxhimer JB. et al. Inverse correlation between heparan sulfate composition and heparanase-1 gene expression in thyroid papillary carcinomas: a potential role in tumor metastasis. Clin Cancer Res 2003; 9 (16, Pt 1): 5968-5979
    PubMedGoogle Scholar
  • 32 Jung O, Trapp-Stamborski V, Purushothaman A. et al. Heparanase-induced shedding of syndecan-1/CD138 in myeloma and endothelial cells activates VEGFR2 and an invasive phenotype: prevention by novel synstatins. Oncogenesis 2016; 5: e202
    CrossrefPubMedGoogle Scholar
  • 33 Yang Y, Macleod V, Miao HQ. et al. Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis. J Biol Chem 2007; 282 (18) 13326-13333
    CrossrefPubMedGoogle Scholar
  • 34 Maurice-Dror C, Litvak M, Keren-Politansky A, Ackerman S, Haim N, Nadir Y. Circulating heparan sulfate chains and body weight contribute to anti-Xa levels in cancer patients using the prophylactic dose of enoxaparin. J Thromb Thrombolysis 2020; 50 (01) 112-122
    CrossrefPubMedGoogle Scholar
  • 35 Nevo N, Ghanem S, Crispel Y. et al. Heparanase level in the microcirculation as a possible modulator of the metastatic process. Am J Pathol 2019; 189 (08) 1654-1663
    CrossrefPubMedGoogle Scholar
  • 36 Axelman E, Henig I, Crispel Y. et al. Novel peptides that inhibit heparanase activation of the coagulation system. Thromb Haemost 2014; 112 (03) 466-477
    Article in Thieme ConnectPubMedGoogle Scholar
  • 37 Crispel Y, Axelman E, Tatour M. et al. Peptides inhibiting heparanase procoagulant activity significantly reduce tumour growth and vascularisation in a mouse model. Thromb Haemost 2016; 116 (04) 669-678
    Article in Thieme ConnectPubMedGoogle Scholar
  • 38 Lanir N, Aharon A, Brenner B. Procoagulant and anticoagulant mechanisms in human placenta. Semin Thromb Hemost 2003; 29 (02) 175-184
    Article in Thieme ConnectPubMedGoogle Scholar
  • 39 Haimov-Kochman R, Friedmann Y, Prus D. et al. Localization of heparanase in normal and pathological human placenta. Mol Hum Reprod 2002; 8 (06) 566-573
    CrossrefPubMedGoogle Scholar
  • 40 McCarthy C, Cotter FE, McElwaine S. et al. Altered gene expression patterns in intrauterine growth restriction: potential role of hypoxia. Am J Obstet Gynecol 2007; 196 (01) 70.e1-70.e6
    CrossrefPubMedGoogle Scholar
  • 41 Udagawa K, Yasumitsu H, Esaki M. et al. Subcellular localization of PP5/TFPI-2 in human placenta: a possible role of PP5/TFPI-2 as an anti-coagulant on the surface of syncytiotrophoblasts. Placenta 2002; 23 (2-3): 145-153
    CrossrefPubMedGoogle Scholar
  • 42 Salem HT, Westergaard JG, Hindersson P, Lee JN, Grudzinskas JG, Chard T. Maternal serum levels of placental protein 5 in complications of late pregnancy. Obstet Gynecol 1982; 59 (04) 467-471
    PubMedGoogle Scholar
  • 43 Deitcher SR, Gomes MP. The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review. Cancer 2004; 101 (03) 439-449
    CrossrefPubMedGoogle Scholar
  • 44 Rosing J, Middeldorp S, Curvers J. et al. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet 1999; 354 (9195): 2036-2040
    CrossrefPubMedGoogle Scholar
  • 45 Elkin M, Cohen I, Zcharia E. et al. Regulation of heparanase gene expression by estrogen in breast cancer. Cancer Res 2003; 63 (24) 8821-8826
    PubMedGoogle Scholar
  • 46 Treger S, Ackerman S, Kaplan V, Ghanem S, Nadir Y. Progesterone type affects the increase of heparanase level and pro-coagulant activity mediated by the estrogen receptor. Human Reproduction 2021; 36: 61-69
    PubMedGoogle Scholar
  • 47 Gunatillake T, Chui A, Fitzpatrick E. et al. Decreased placental glypican expression is associated with human fetal growth restriction. Placenta 2019; 76: 6-9
    CrossrefPubMedGoogle Scholar
  • 48 Hofmann-Kiefer KF, Knabl J, Martinoff N. et al. Increased serum concentrations of circulating glycocalyx components in HELLP syndrome compared to healthy pregnancy: an observational study. Reprod Sci 2013; 20 (03) 318-325
    CrossrefPubMedGoogle Scholar
  • 49 Oh JH, Kim YK, Jung JY, Shin JE, Chung JH. Changes in glycosaminoglycans and related proteoglycans in intrinsically aged human skin in vivo. Exp Dermatol 2011; 20 (05) 454-456
    CrossrefPubMedGoogle Scholar
  • 50 Kurdykowski S, Mine S, Bardey V. et al. Ultraviolet-B irradiation induces epidermal up-regulation of heparanase expression and activity. J Photochem Photobiol B 2012; 106: 107-112
    CrossrefPubMedGoogle Scholar
  • 51 Iriyama S, Matsunaga Y, Takahashi K, Matsuzaki K, Kumagai N, Amano S. Activation of heparanase by ultraviolet B irradiation leads to functional loss of basement membrane at the dermal-epidermal junction in human skin. Arch Dermatol Res 2011; 303 (04) 253-261
    CrossrefPubMedGoogle Scholar
  • 52 Konno K, Arai H, Motomiya M. et al. A biochemical study on glycosaminoglycans (mucopolysaccharides) in emphysematous and in aged lungs. Am Rev Respir Dis 1982; 126 (05) 797-801
    PubMedGoogle Scholar
  • 53 Nishiguchi KM, Ushida H, Tomida D, Kachi S, Kondo M, Terasaki H. Age-dependent alteration of intraocular soluble heparan sulfate levels and its implications for proliferative diabetic retinopathy. Mol Vis 2013; 19: 1125-1131
    PubMedGoogle Scholar
  • 54 Nitschmann E, Berry L, Bridge S. et al. Morphological and biochemical features affecting the antithrombotic properties of the aorta in adult rabbits and rabbit pups. Thromb Haemost 1998; 79 (05) 1034-1040
    Article in Thieme ConnectPubMedGoogle Scholar
  • 55 Nitschmann E, Berry L, Bridge S. et al. Morphologic and biochemical features affecting the antithrombotic properties of the inferior vena cava of rabbit pups and adult rabbits. Pediatr Res 1998; 43 (01) 62-67
    CrossrefPubMedGoogle Scholar
  • 56 Campisi J. Aging, tumor suppression and cancer: high wire-act!. Mech Ageing Dev 2005; 126 (01) 51-58
    CrossrefPubMedGoogle Scholar
  • 57 Bochenek ML, Bauer T, Gogiraju R. et al. The endothelial tumor suppressor p53 is essential for venous thrombus formation in aged mice. Blood Adv 2018; 2 (11) 1300-1314
    CrossrefPubMedGoogle Scholar
  • 58 Hardak E, Peled E, Crispel Y. et al. Heparan sulfate chains contribute to the anticoagulant milieu in malignant pleural effusion. Thorax 2020; 75 (02) 143-152
    CrossrefPubMedGoogle Scholar